Efficacy and Safety of Vorapaxar in Non–ST‐Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery

By  

JOURNAL OF THE AMERICAN HEART ASSOCIATION, Vol. 4, Iss. 12, 2015-12 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Low-molecular-weight heparin compared with unfractionated heparin for patients with non–ST-segment elevation acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors: Results from the CRUSADE initiative

By Singh Kanwar   Roe Matthew   Peterson Eric   Chen Anita   Mahaffey Kenneth   Goodman Shaun   Harrington Robert   Smith Sidney   Gibler W.   Ohman E.   Pollack Charles  

Journal of Thrombosis and Thrombolysis, Vol. 21, Iss. 3, 2006-06 ,pp. : 211-220

Springer Publishing Company

Access to resources Recommend Favorite

Balancing the benefits and risks of antiplatelet agents in patients with non-ST-segment elevated acute coronary syndromes and undergoing percutaneous coronary intervention

By Saucedo Jorge  

Journal of Thrombosis and Thrombolysis, Vol. 30, Iss. 2, 2010-08 ,pp. : 200-209

Springer Publishing Company

Access to resources Recommend Favorite

Practical approach to incorporating new studies and guidelines for antiplatelet therapy in the management of patients with non-ST-segment elevation acute coronary syndrome

By Boden W.E.  

The American Journal of Cardiology, Vol. 93, Iss. 1, 2004-01 ,pp. : 69-72

Elsevier

Access to resources Recommend Favorite

Comparison of Risk Prediction With the CKD‐EPI and MDRD Equations in Non–ST‐Segment Elevation Acute Coronary Syndrome

By  

Clinical Cardiology, Vol. 39, Iss. 9, 2016-09 ,pp. : 507-515

John Wiley & Sons Inc

Access to resources Recommend Favorite